Home › Trials › NCT05426720
Clinical trial Recruiting at 2 sites Observational Ages 25 to 60 Men only

Investigating lung damage after tuberculosis treatment

Official title: Risk Factors and Biomarkers for Post-tuberculosis Lung Damage in a Chinese Cohort: Protocol for a Prospective Observational Study

Run by Peking University Third Hospital · NCT05426720 · Data updated 2026-11-12

This study is trying to see how many people have lung damage after finishing tuberculosis treatment and how smoking and other factors affect their breathing and lung health.

Quick facts

Study typeObservational
Ages25 Years to 60 Years
SexMen only
Enrollment400 (estimated)
SponsorPeking University Third Hospital
Academic / other
Locations2 sites (Beijing and 1 other locations)
StatusRecruiting
StartedJanuary 1, 2022
Main results expectedDecember 31, 2024
Study endsDecember 31, 2027
Registry record updatedJune 22, 2022
Trial IDNCT05426720 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are male patients aged 25-60 years who have newly diagnosed active pulmonary tuberculosis.

Probably not a fit

Patients with multidrug-resistant TB, HIV-positive status, or significant comorbidities such as lung cancer or severe cardiovascular diseases may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective observational study aims to assess the incidence of post-tuberculosis lung damage (PTLD) and explore the influence of smoking and other factors on lung function and respiratory symptoms in patients who have completed tuberculosis treatment. It will enroll 400 adult male patients aged 25-60 years with newly confirmed active pulmonary TB, collecting baseline data and conducting follow-up assessments over three years. The study will analyze clinical symptoms, lung function, chest CT findings, and inflammatory biomarkers to develop prognostic and therapeutic strategies for PTLD.

Why it matters

Potential benefit: If successful, this study could lead to improved management and treatment strategies for patients suffering from post-tuberculosis lung damage.

How similar studies have gone: While the investigation of post-tuberculosis lung damage is relatively novel, similar studies have shown that understanding risk factors can lead to better patient outcomes.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

Male patients aged 25-60 years newly diagnosed with active pulmonary TB.

Exclusion Criteria:

1. patients with positive sputum smear or TB culture results;
2. human immunodeficiency virus-positive patients;
3. patients infected with multidrug-resistant TB;
4. patients with malignant neoplasms (e.g., lung cancer) or severe cardiovascular and cerebrovascular diseases;
5. non-compliant patients who were unable to complete the lung function tests;
6. patients without lung parenchymal destruction (such as tuberculous pleurisy). -

Where it's running

  • Peking University Third Hospital
    Beijing, China     Recruiting
  • Beijing Geriatric Hospital
    Beijing, China     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Peking University Third Hospital 93
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.